Armata Pharmaceuticals (ARMP)
(Real Time Quote from BATS)
$2.19 USD
+0.09 (4.29%)
Updated Sep 19, 2024 02:33 PM ET
After-Market: $2.19 0.00 (0.00%) 4:10 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARMP 2.19 +0.09(4.29%)
Will ARMP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARMP
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
Other News for ARMP
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
Armata Pharmaceuticals Updates Progress and Corporate Presentation
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
Armata Pharmaceuticals Welcomes David House as New SVP of Finance